The report "ATP Assays Market by Product (Consumables (Reagents, Microplate), Instruments (Luminometer, Spectrophotometer)), Application (Contamination, Disease Testing, Drug Discovery), End User (Hospitals, Pharmaceuticals, F&B, Academics) - Global Forecast to 2028", is projected to reach USD 0.5 billion by 2028 from USD 0.3 billion in 2023, at a CAGR of 7.8% during the forecast period. The ATP Assays market is mainly driven by factors such as growing drug discovery & development studies, growing penetration of CROs, increasing demand for cell-based assays in research, growing investments by pharmaceutical and biotechnology companies are some of the key factors driving the market for ATP assays.
Browse 166 market data Tables and 49 Figures spread through 242 Pages and in-depth TOC on "ATP Assays Market by Product (Consumables (Reagents, Microplate), Instruments (Luminometer, Spectrophotometer)), Application (Contamination, Disease Testing, Drug Discovery), End User (Hospitals, Pharmaceuticals, F&B, Academics) - Global Forecast to 2028"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/atp-assay-market-223438780.html
The consumables & accessories segment is accounted for largest share of the market during the forecast period
On the basis of product, The ATP assays market comprises consumables & accessories as well as instruments, with the consumables & accessories segment holding a significant portion. This dominance can be attributed to the the growing demand for tumor testing and cell proliferation (specifically in cancer) driven by an upsurge in chronic diseases, and the frequent procurement of consumables by pharmaceutical and biotechnology firms.
The contamination testing segment accounted for the largest share of the market during the forecast period.
On the basis of application, The ATP assays market is bifurcated into contamination testing, disease testing, and drug delivery & development segments. The significant portion of the contamination testing segment is due to various factors such as the surge in drug discovery activities following the COVID-19 pandemic, and the necessity for cleaning and disinfecting environmental surfaces in hospitals.
The pharmaceutical & biotechnology segment accounted for the largest share of the market in 2022
On the basis of end users, The ATP assays market is categorized into pharmaceutical & biotechnology companies, the food & beverage industry, hospitals & diagnostic laboratories, and academic & research institutes. The dominance of this segment can be attributed to several key factors. These include the presence of a large number of pharmaceutical players who are making substantial investments in this market, the growing regulatory approvals for cell culture-based vaccines that necessitate the use of ATP assays in contamination testing, the expansion of commercial activities by various pharmaceutical companies, the rising demand for cell and gene therapies to address chronic diseases, and significant research and development efforts in the pharmaceutical & biopharmaceutical sector.
APAC to witness the highest growth during the forecast period.
In 2022, North America accounted for the largest share the ATP assays market, followed by Europe, Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the availability of government and private funding for life science research, growing penetration of CROs, comprehensive drug development regulations, and the presence of major players in the ATP assays market in this region.
The prominent players in this market are Thermo Fisher Scientific, Inc. (US), Promega Corporation (US), Merck KGaA (Germany), PerkinElmer, Inc. (US), Agilent Technologies, Inc. (US), Abcam plc (UK), Lonza Group (Switzerland), Neogen Corporation (US), 3M (US), Danaher Corporation (US), PromoCell GmbH (Germany), Geno Technology, Inc. (US), Abnova Corporation (Taiwan), AAT Bioquest,Inc. (US), BioThema AB (Sweden), Elabscience Biotechnology Inc. (US), MBL International Corporation (US), Biotium (US), Creative Bioarray (US), Canvax Biotech S.L. (Spain), Ruhof Corporation (US), Charm Sciences, Inc. (US), Bio Shield Tech, LLC (US), Cayman Chemical (US), and Cell Signaling Technology,Inc. (US).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441